Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 3 de 3
Filtrer
Plus de filtres











Base de données
Gamme d'année
1.
Pharm Dev Technol ; 27(6): 654-664, 2022 Jul.
Article de Anglais | MEDLINE | ID: mdl-35850635

RÉSUMÉ

Nanotechnological products have been used as strategies to optimize the therapy and minimize the side effects of topical corticoids. The objective of this study was to develop hydrogels by the addition of sclerotium gum to the suspensions of desonide-loaded açai oil-based nanocapsules and to study their biological effect using an animal model of acute skin inflammation. The hydrogels presented a pH compatible with topical application (4.4 to 5.0), nanometric mean diameter (131 to 165 nm), pseudoplastic behavior, and stability under room conditions during 30 days. The in vitro skin permeation/penetration study demonstrated that a higher amount of desonide (p < 0.05) was retained in the epidermis from the nanotechnological-hydrogels (0.33 to 0.36 µg.cm2) in comparison to the commercial gel cream (0.16 µg.cm2). In the dermis, the nanostructured hydrogels promoted a lower DES retention compared to the non-nanostructured formulations (p < 0.05). This result may indicate a smaller amount of drug reaching the bloodstream and, thus, fewer side effects can be expected. Concerning the anti-inflammatory effect, the developed hydrogels reduced both ear edema and inflammatory cell infiltration, showing an effect comparable to the commercially available formulation, which presents twice the drug concentration. The hydrogels developed may be considered a promising approach to treat dermatological disorders.


Sujet(s)
Nanocapsules , Animaux , Anti-inflammatoires/usage thérapeutique , Désonide/pharmacologie , Glucocorticoïdes , Hydrogels
2.
J Photochem Photobiol B ; 199: 111606, 2019 Oct.
Article de Anglais | MEDLINE | ID: mdl-31522112

RÉSUMÉ

This study aimed to develop Eudragit® RL 100 nanocapsules loaded with desonide (DES) using açai oil (AO) or medium chain triglycerides (MCT) as oil core. Pre-formulation study showed that AO and MCT are suitable for nanocapsules preparation. The nanocapsules prepared with AO and MCT presented mean particle size around 165 and 131 nm, respectively; polydispersity index values <0.20, positive zeta potential values, drug content close to the theoretical value (0.25 mg mL-1), and DES encapsulation efficiency around 81%, regardless of the oil core (AO or MCT). Considering the photoinstability reported to DES, photodegradation studies were performed. The UV-A (365 nm) and UV-C (254 nm) photodegradation studies revealed less DES degradation when associated to the nanocapsules containing AO in comparison to those with MCT. The in vitro release study showed a biphasic release profile for both nanocapsule suspensions: an initial burst effect followed by a prolonged DES release. In addition, the formulations were considered non-phototoxic at 0.5 mg mL-1 when tested on 3 T3 murine fibroblasts and HaCaT human keratinocytes using the MTT and NRU viability assays. The irritant potential of the prepared nanocapsules and DES in free form were evaluated by HET-CAM method. All formulations were classified as slightly irritant, including the non-associate DES. In conclusion, the nanocapsule formulations developed in this study may be promising for therapeutic applications.


Sujet(s)
Anti-inflammatoires/composition chimique , Désonide/composition chimique , Euterpe/composition chimique , Nanocapsules/composition chimique , Huiles végétales/composition chimique , Poly(acides méthacryliques)/composition chimique , Animaux , Anti-inflammatoires/pharmacologie , Lignée cellulaire , Survie cellulaire/effets des médicaments et des substances chimiques , Désonide/pharmacologie , Préparation de médicament/méthodes , Libération de médicament , Stabilité de médicament , Humains , Lumière , Souris , Taille de particule , Photolyse , Huiles végétales/pharmacologie , Suspensions/composition chimique , Triglycéride/composition chimique
3.
Talanta ; 181: 182-189, 2018 May 01.
Article de Anglais | MEDLINE | ID: mdl-29426498

RÉSUMÉ

Tipranavir (TPV) is one of the most recently developed protease inhibitors (PI) and it is specially recommended for treatment-experienced patients who are resistant to other PI drugs. In this work, a simple and friendly environmental CZE stability-indicating method to assay TPV capsules was developed and two TPV organic impurities were identified by high resolution mass spectrometry (HRMS). The optimized analytical conditions were: background electrolyte composed of sodium borate 50mM, pH 9.0 and 5% of methanol; voltage + 28kV; hydrodynamic injection of 5s (100mbar), detection wavelength 240nm, at 25°C. The separation was achieved in a fused silica capillary with 50µm × 40cm (inner diameter × effective length), using furosemide as internal standard. All the validation parameters were met and the method was specific, even in the presence of degradation products and impurities. Oxidation was indicated as the main degradation pathway among those evaluated in this study (acidic, alkaline, thermal, photolytic and oxidative) and it showed a second order degradation kinetic, under the conditions used in this study. The main oxidation product and an organic impurity detected in the standard were characterized by Q-TOF, and both of them correspond to oxidation products of TPV.


Sujet(s)
Contamination de médicament/prévention et contrôle , Électrophorèse capillaire/méthodes , Spectrométrie de masse/méthodes , Pyridines/analyse , Pyrones/analyse , Capsules , Concentration en ions d'hydrogène , Méthanol/composition chimique , Oxydoréduction , Pyridines/composition chimique , Pyrones/composition chimique , Reproductibilité des résultats , Sulfonamides
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE